



King's Research Portal

DOI:

[10.3389/fgene.2022.866474](https://doi.org/10.3389/fgene.2022.866474)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Ahamad, S., Ali, H., Secco, I., Giacca, M., & Gupta, D. (2022). Anti-fungal drug anidulafungin inhibits SARS-CoV-2 Spike induced syncytia formation by targeting ACE2-Spike protein interaction. *Frontiers of Genetics*, 13, Article 866474. <https://doi.org/10.3389/fgene.2022.866474>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Anti-fungal drug anidulafungin inhibits SARS-CoV-2 Spike induced syncytia formation by targeting ACE2-Spike protein interaction

Shahzaib Ahamad^{1*}, Hashim Ali^{2,3*}, Ilaria Secco², Mauro Giacca^{2#} and Dinesh Gupta^{1#}

¹Translational Bioinformatics Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.

²King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine & Sciences, London UK

³Division of Virology, Department of Pathology, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.

* Both authors contributed equally

Senior authors

Address for correspondence:

Mauro Giacca, MD PhD
King's College London
School of Cardiovascular Medicine & Sciences
The James Black Centre
125 Coldharbour Lane
London SE5 9NU
Phone +44 207 848 1309
Email: mauro.giacca@kcl.ac.uk

Dinesh Gupta, PhD
Translational Bioinformatics Group,
International Centre for Genetic Engineering and Biotechnology (ICGEB)
Aruna Asaf Ali Marg, New Delhi-110067, India
Email: dinesh@icgeb.res.in

Abstract

Drug repositioning continues to be the most practicable possibility to treat COVID-19 patients immediately. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) virus enters target cells by binding to the ACE2 receptor via its Spike (S) glycoprotein. We used molecular docking-based virtual screening approaches to categorize potential antagonists halting ACE2-Spike interactions utilizing 450 FDA-approved chemical compounds. Three drug candidates (i.e., Anidulafungin, Lopinavir and Indinavir) were selected, which show high binding affinity towards the ACE2 receptor. The conformational stability of selected docked complexes was analyzed through Molecular Dynamics (MD) simulations. The MD simulation trajectories were assessed and monitored for ACE2 deviation, residues fluctuation, the radius of gyration, solvent accessible surface area and free energy landscapes. The inhibitory activities of the selected compounds were eventually tested *in-vitro* using Vero and HEK-ACE2 cells. Interestingly, besides inhibiting SARS-CoV-2 S-induced syncytia formation, anidulafungin and lopinavir also blocked S-pseudo particle entry into target cells. Altogether, anidulafungin and lopinavir ranked as the most effective amongst all the tested drugs against the ACE2 receptor-S interaction. Based on these findings, we propose that anidulafungin is a novel potential drug targeting ACE2, which warrants further investigation for COVID-19 treatment.

Keywords: SARS-CoV-2, COVID-19, ACE2, Virtual screening and MD simulations, syncytia.

1 Introduction

COVID-19 consists of a spectrum of syndromes from a mild, flu-like illness to severe pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus (Zhou et al., 2020). Its severity is linked to lung epithelial destruction, thrombosis, hyperimmune-mediated damage (Bussani et al., 2020; Zhou et al., 2020; Zhu et al., 2020; Buchrieser et al., 2021). Additionally, an abnormal dysmorphic cellular characteristic is the presence of large infected multinucleated cells, predominately comprised of pneumocytes (Bussani et al., 2020; Braga et al., 2021; Sanders et al., 2021). The disease has rapidly spread globally, prompting the WHO in March 2020 to declare it as a worldwide pandemic. As per WHO, till February 19, 2022, SARS-CoV-2 is estimated to have infected over 418,650,474 people and caused over 5,856,224 deaths (WHO, 2022).

SARS-CoV-2 is an enveloped virus with a positive-sense single-stranded RNA that belongs to the beta-coronavirus genera of coronaviruses and exploits the human ACE2 receptor to enter the host cells (Hoffmann et al., 2020; Yan et al., 2020), such as SARS-CoV (Wrapp et al., 2020). The spike (S) protein present in the outer envelope of the virus binds the ACE2 receptor expressed on target cells along with other membrane proteins (NPR1 (Cantuti-Castelvetri et al., 2020), TMPRSS2 (Hoffmann et al., 2020) and Furin (Johnson et al., 2020; Peacock et al., 2021) (which assist the binding or entry), leading to the access of the virus to the target cells. After binding with the ACE2 molecules, the conformational changes in the S protein lead to the fusion of the viral envelope with the host cell membrane and subsequent transfer of the RNA viral genome into the cells (Hoffmann et al., 2020). Apart from interacting with ACE2, S protein is also predicted to interact with Glucose Regulated Protein 78 (GRP78) or Bip which plays a role in virus internalization (Ibrahim et al., 2020; Elfiky and Ibrahim, 2022). Another study reported that the GRP78 is vital for ACE2 trafficking and stability (Carlos et al., 2021). Several groups have conducted computational studies as well experiments to study the interactions involving S protein and ACE2 receptor. To target and disrupt the interactions by exploring repurposed drugs or novel inhibitors, attempts have been made to design ligands targeting S protein (Xiu et al., 2020; Wang et al., 2021) as well ACE2 receptors (Ahmad et al., 2021). Despite the availability of several vaccines to treat COVID-19 and reduce the viral spread and disease severity, COVID-19 still requires novel therapeutics to fight the newly emerging SARS-CoV-2 variants and overcome the significant limitations in vaccine production and distribution, which hamper worldwide effective immunization. Since its appearance, the inherited Wuhan strain has been replaced by variants harbouring various mutations in the viral genome (Otto et al., 2021; Singh et al., 2021). Several of these mutations occur in the highly antigenic S protein, which enriched several of the variants with the ability to escape part of the neutralizing antibody response (Weisblum et al., 2020; Liu et al., 2021; Planas et al., 2021; Rees-Spear et al., 2021; Starr et al., 2021). Several available vaccines have significantly reduced efficacy against these newly emerged variants (Pouwels et al., 2021; Sanderson, 2021). Various drugs have been proven effective against COVID-19 in controlled clinical trials, including remdesivir (Beigel et al., 2020), corticosteroid (Sterne et al., 2020) and a few monoclonal antibodies (Marovich et al., 2020; Taylor et al., 2021). However, none of these drugs are curative and, in several instances, their clinical effect is quite modest. In addition, some of the available treatments, particularly those with monoclonal antibodies, show diminished activity with the emerging variants. Given the importance of SARS-CoV-2, its transmission and rapid worldwide spread, it is thus crucial to rapidly generate new therapeutic approaches, especially to deal with newly emerging SARS-CoV-2 mutants.

The ACE2 receptor plays an essential role in transmitting the virus to the target host cells, hence here we aimed to identify a potential antagonist against the ACE2 receptor, which can

inhibit the entry of the virus into the human cells. We screened 450 FDA-approved compounds with antiviral properties towards the active pocket of ACE2 receptor using molecular docking-based virtual screening, followed by MD simulation subsequently, in vivo validation of chosen drugs. Furthermore, MD simulations further examined the stability of ligand-protein complexes, and free energy of binding was calculated using the (MMGB/SA) ΔG methods. Here, we found that two drugs, anidulafungin and lopinavir, effectively block S-induced cell-cell fusion events and S-viral particles entry. As both S-mediated syncytia formation and entry of S-viral particles into the cells require functional ACE2-S interactions, we conclude that anidulafungin and lopinavir effectively block the formation of the ACE2-S complex.

2 Materials and methods

2.1 Selection of FDA-approved antiviral and ACE2 structure

Drug candidates were selected among antiviral datasets from published literature to identify the novel drugs which potentially interfere with the SARS-CoV-2 replication by inhibiting Spike-ACE2 interactions (Ghahremanpour et al., 2020; Heiser et al., 2020; Jeon et al., 2020; Jin et al., 2020; Ku et al., 2020; Nguyenla et al., 2020; Riva et al., 2020; Touret et al., 2020; Weston et al., 2020; Yuan et al., 2020; Ahamad et al., 2021b; Chen et al., 2021; Dittmar et al., 2021; Ellinger et al., 2021; Ginex et al., 2021; Han et al., 2021; Mirabelli et al., 2021). The structure of the ACE2 receptor (PDB ID: 6M17) was downloaded from the Protein Data Bank (Goodsell et al., 2020).

2.2 Computational

The MD simulations were carried out on High Performance Computing (HPC) with 2 x 20 Cores Processors, 128 GB RAM; NVIDIA graphics card (GPU RTX2080 11 GB); installed on an International Business Machines (IBM) POWER 9 CPU server.

2.3 Molecular Docking

To predict the preferred binding pocket on the ACE2 surface, molecular docking-based virtual screening was performed using Flare 5 and binding affinities calculated. The compounds were docked using Flare version 5.0, which incorporates BioMolTech's LeadFinder docking algorithm and combines its docking engine with genetic algorithm search containing local optimization procedures, enabling efficient sampling of ligand poses refinement. The Volume of the grid box was 287154 Å^3 and the axis were set to be X: 116.403, Y:97.474 and Z: 183.867 to cover all the amino acids in the box. It includes three different scoring functions (viz. LF dG, LF VSscore, LF Rank Score) for accurately predicting 3D docked ligand poses, the LF RankScore were selected for protein-ligand binding energy and rank ordering of active and inactive compounds in virtual screening experiments. The 2D plot was generated to study residue-ligand interactions, using Schrödinger Maestro version 12.8.117, release 2021-2 suite (Schrödinger LLC, Cambridge, MA).

2.4 GRONingen MACHine for Chemical Simulations (GROMACS)

We used the general methodology to perform MD simulations of native ACE2 and the best-docked complexes using GROMACS (V5.18.3) (Abraham et al., 2015). For the MD simulation of the docked complexes, suitable force field parameters required for the ligand/drug topology which cannot be assigned using GROMACS. Hence, PRODRG server was used to generate drug topologies and coordinate files (Schuttelkopf and van Aalten, 2004). We used GROMOS9643a1 force field for native and drug-protein complex, viz. ACE2-anidulafungin, ACE2-lopinavir, ACE2-indinavir and ACE2-MLN-4670 (Van Der Spoel et al., 2005). Furthermore, systems were solvated using a Simple Point Charge (SPC) water model in a cubic box (Price and Brooks, 2004). 0.15M counter ions of Sodium (Na⁺) and Chlorine (Cl⁻) were added to the simulation box for the system neutralization. All the neutralized systems were energy minimized using the steepest descent followed by conjugate gradient methods (50000 steps for each). The system equilibration was achieved under the regulation of volume (NVT) and pressure (NPT) ensembles. The NVT ensemble was subjected to a constant temperature of 300K and a constant pressure of 1bar. The Hydrogen (H) atoms were confined to equilibrium distances and periodic boundary conditions using the SHAKE algorithm. Additionally, the long-range electrostatic forces were defined using the Particle Mesh Ewald (PME) method (Lee et al., 2016). The cut-offs for Van der Waals and coulombic interactions were set at 1.0 nm (Wang et al., 2016). The bonds and angles were constrained using the LINCS algorithm. Moreover, after a successful NPT ensemble run, the production run was performed for 100ns. The energy, velocity, and trajectory were updated at the time interval of 10ps. For the native ACE2 and the complexes, the MD trajectories were analyzed using GROMACS to calculate several parameters, namely, C α -atom Root Mean Square Deviations (RMSD), Root Mean Square Fluctuations (RMSF) to investigate the relative fluctuations of each residue, Radius of Gyration (Rg) to assess the protein compactness, Solvent Accessible Surface Area (SASA) to estimate the electrostatic contributions of molecular solvation, and Free Energy Landscapes (FEL), as described in our previous publications (Ahamad et al., 2021a; Ahamad et al., 2021b).

2.5 Cells

HEK293T cells (ATCC CRL-3216) were cultured in Dulbecco's modified Eagle medium (DMEM) with 1 g/L glucose (Life Technologies) supplemented with 10% foetal bovine serum (FBS) (Life Technologies) plus a final concentration of 100 IU/ml penicillin and 100 (μ g/ml) streptomycin or without antibiotics were required for transfections.

Vero (WHO) Clone 118 cells (ECACC 88020401) were cultured in Dulbecco's modified Eagle medium (DMEM, Life Technologies) with 1 g/L glucose (Life Technologies) supplemented with 10% heat-inactivated foetal bovine serum (FBS, Life Technologies) plus a final concentration of 100 IU/ml penicillin and 100 (μ g/ml) streptomycin or without antibiotics where required for transfection. Cells were incubated at 37°C, 5% CO₂.

2.6 Plasmids

Human ACE2 (Addgene #1786), pLVTHM/GFP (Addgene #12247), psPAX2 (Addgene 12260), pMD2.G (Addgene #12259) were obtained from Addgene. pAAV-CMV-GFP was obtained from L. Zentilin (Molecular Medicine Lab, ICGEB). pAAV-Spike-V5 and pAA-Spike-d19-V5 SARS-CoV-2 spike expression vectors were used previously (Braga and Ali et al. Nature 2021).

2.7 Antibodies

Antibodies against the following proteins were used: ACE2 (Abcam, ab15348), SARS-CoV-2 Spike (GeneTex GTX632604), V5-488 (Thermo Fisher Scientific, 377500A488), α -beta-

actin-HRP (Sigma-Aldrich), mouse-HRP (Abcam, ab6789) and rabbit-HRP (Abcam, ab205718).

2.8 Plasmids DNA transfections

Plasmid expressing human ACE2 reverse transfection were performed in 96 well plate, 100ng of plasmids were diluted in 25ul of Opti-MEM (Life Technologies) and mixed with the transfection reagent (FuGENE HD, Promega) using a ratio of 1 μ g pDNA:3 μ l FugeneHD. The transfection mixes were incubated for 25 min at RT and added to the 96 well plates (Cell Carrier Ultra 96, Perkin Elmer).

Vero cells (6.5×10^3) or HEK293-ACE2(8×10^3) cells were seeded in each well. After 24 hrs of transfections, 100ng of either pEC117-Spike-V5 expression plasmid was transfected using a standard forward transfection protocol. After 24 hr, cells were fixed in 4% PFA and processed for immunofluorescence.

2.9 Immunofluorescence

After fixation in 4% PFA for 10 min at RT, cells were washed two times with 1xPBS and then permeabilized in same volumes of 0.1% Triton X100 (Sigma-Aldrich 1086431000) for 10 min at RT. Cells were then washed two times 1xPBS and blocked in 2% BSA for 1hr at RT. After blocking, and cells were stained according to the type of staining:

After blocking, a diluted primary antibody (1:500 in 1% BSA SARS-CoV-2 spike antibody or V5-488, was added to each well and incubated overnight at 4 degrees. Cells were then washed two times with 1xPBS, and then a secondary antibody was added (45 μ l/well, diluted 1:500 in 1% BSA) to each well and incubated for 2hr at RT. Cells were then washed two to three times in 1xPBS. Nuclear staining was performed by using Hoechst 33342 (1:5000).

2.10 Image acquisition and analysis

Image acquisition was performed using the Operetta CLS high content screening microscope (Perkin Elmer) with a Zeiss 20x (NA=0.80) objective, a total of 25 fields were acquired per wavelength, well and replicate (~10,000-15,000 cells per well and replicate).

Images were subsequently analysed using the Harmony software (PerkinElmer). Images were first flatfield corrected and Nuclei were segmented using the “Find Nuclei” analysis module (Harmony). The thresholds for image segmentation were adjusted according to the signal to background ratio. The splitting coefficient was set to avoid splitting of overlapping nuclei (Fused cells). The intensity of the green fluorescence(spike/GFP) was calculated using the “Calculate Intensity Properties” module (Harmony). All the cells that scored a nuclear area greater than 4 times (for manual quantification of syncytia, if fused nuclei >3, it counts as a syncytia) the average area of a single nucleus and were simultaneously positive for green (Spike) signal in the cytoplasm area were considered as fused or syncytia. Data were expressed as a percentage of fused cells by calculating the average number of fused cells normalized on the total number of cells per well.

For pseudo particle entry assays: Mean intensities of the segmented nucleus in the 488 (green) channel and the Hoechst channel for each nucleus across all fields were extracted. Each assay plate included negative control as DMSO. Briefly, nuclei were segmented based on Hoechst staining, and cells were then classified as positive or negative depending on the GFP signal. Data were expressed as a percentage of GFP+ cells by calculating the average number of GFP+cells normalized on the total number of cells.

2.11 Pseudo particle production and entry assay

HIV-1 based lentiviral system was used to produce SARS-CoV-2 Spike pseudotyped particles in HEK293T cells by the co-transfection of pMD2.G or pAAV-Spike(d19), psPAX2

(packing vector) and PLVTHM(GFP) as described previously (Ali et al., Nature communications 2019). Viral supernatants were collected after 48hr of transfection and centrifuged at 3000rpm for 10min at 4 degrees. The supernatant was then filtered with a 0.45 μ m pore size filter, aliquoted and stored at -80°C. For pseudo-particle entry, 1hr before Spike pseudo particles transduction, HEK293-ACE2 cells were treated with selected drugs and control cells were treated with DMSO. After 36 hours, cells were fixed; nuclei were labelled with Hoechst and assessed for pseudo particles transduction efficiency based on GFP positive cells.

2.12 Western blotting

After 20-24hrs of drugs treatment, Vero cells were processed for western blot analysis. Equal amounts of total cellular proteins (15 μ g), as measured with the BCA (ThermoFisher, 23227), were resolved by electrophoresis in 4-20% gradient polyacrylamide gels (Mini-PROTEAN, Biorad) and transferred to nitrocellulose/PVDF membranes (GE Healthcare). Membranes were blocked at RT for 60 min with PBST (PBS + 0.1% Tween-20) with 5% skim milk powder (Cell signalling, 9999). Blots were then incubated (4 °C, overnight) with primary antibodies against ACE2 (diluted 1:1000), and α -tubulin (diluted 1:10000). Blots were washed three times (10 min each) with PBST. For standard Western blotting detection, blots were incubated with either anti-rabbit HRP-conjugated antibody (1:5000) or anti-mouse HRP-conjugated antibody (1:10,000) for 1hr at RT. After washing three times at RT with PBST (10min each), blots were developed with ECL (Amersham).

3 Results

3.1 In silico screening of inhibitors targeting ACE2-Spike protein interactions.

Functional ACE2-S interaction is essential for SARS-CoV-2 entry into host cells, as shown in (Figure 1A). Detailed structural analysis proved that both SARS-CoV-2 and SARS-CoV S protein strongly bind with ACE2 receptors (Lan et al., 2020; Magro et al., 2021). Therefore, to identify drugs that could inhibit the ACE2-S interactions and potentially viral replication, we screened the 450 drugs (Supplementary Table 1) by exploiting the molecular docking approach (Figure 1B and Figure 2A-C). Here, we found that several compounds show a strong affinity towards ACE2 receptor, but we selected the top three compounds, namely anidulafungin, lopinavir and indinavir, showing binding affinity more than MLN-4670, which is a known enzymatic inhibitor of ACE2 (Dales et al., 2002a) (Figure 2B-C, Suppl. Figure 1A-C). Detailed molecular interactions and properties of the four selected docked complexes are shown in Table 1. In the ACE2-anidulafungin complex, anidulafungin forms 2 Hydrogen(H) bonds with Arg518 and Thr371 amino acid residues (Figure 2B-C) and hydrophobic bonds with 32 amino acids (shown in Table 1) together with one Zn-ion at the binding pocket of the ACE2 receptor. Similarly, in the lopinavir-ACE2 complex, lopinavir forms 1-H bonds with Glu398 and hydrophobic bonds with 38 amino acids (shown in Table 1). Indinavir interacts with Gly395 and Glu402 by 2H-bonds, hydrophobic bonds with 32 amino acid residues and Zn ions (shown in Table 1). The docking and 2D plot are shown in (Suppl. Figure 1D-F). However, MLN-4760 interacts with ACE2 by forming one H-bond with Glu402 (Supplementary Figure 1C, and 1F) and hydrophobic bonds with 25 amino acid residues and a Zn metal ion (shown in Table 1).

Out of all the tested compounds, three drugs show high binding affinities towards ACE2 compared to MLN-4760, a known enzymatic inhibitor of ACE2. So, potentially these drugs might inhibit SARS-CoV-2 replication by interfering with the formation of functional ACE2-S interactions.

3.2 Anidulafungin forms the most stable complex with ACE2 receptor in the molecular dynamics (MD) simulations

To investigate molecular interactions of the docked complexes further, we performed MD simulations of ACE2-native, three selected docked complexes (ACE2-anidulafungin, ACE2-lopinavir, ACE2-indinavir) and ACE2-MLN-4760 for 100ns. The stability, interaction profile and structural parameters including RMSD, RMSF, Rg, SASA, Free energy calculations were also evaluated throughout the simulation run time to select the most stable receptor-drug complex.

In RMSD analysis, native ACE2 showed steady RMSD and revealed a threshold of ~ 0.44 nm towards the binding with ACE2 under given simulation conditions (**Figure 3A**). The docking complexes of ACE2 with lopinavir, indinavir and MLN-4760 noticeably reached equilibrium with average RMSD values of 0.45 nm, 0.41nm and 0.41nm, respectively. The compounds lopinavir revealed a high drift in the average RMSD values. However, the average RMSD values of the indinavir and MLN-4760 remained same.

The RMS deviation of C α -atoms remained stable throughout the simulation with a slight difference in the values, but proposed one complex with anidulafungin, indicating strong binding due to polar interaction with Arg518 and Thr371 residues as well as various non-polar interactions. Anidulafungin displayed the least RMSD fluctuations at the ACE2 binding pocket compared to the other drug compounds. The overall results suggested that the anidulafungin was reliably stable among all the complexes.

Secondly, RMS-fluctuations play a crucial role in identifying the flexible and rigid regions of drug-receptor complexes. Hence, RMSF calculations were performed to measure the average atomic flexibility of the C α -atoms of ACE2 receptor alone and in complex with the tested compounds. The average RMSF values were- Native-ACE2 (0.18 nm), anidulafungin (0.14nm), lopinavir (0.18nm), indinavir (0.15nm) and MLN-4760 (0.18nm) (**Figure 3B**). Interestingly, we observed that the ACE2-anidulafungin complex showed a low degree of fluctuations compared to other docked complexes and native-ACE2. However, lopinavir and indinavir displayed the highest degree of fluctuations and hence comparatively less stable. The above-mentioned comparative analysis of C α -RMSF confirms a high level of flexibility caused by the presence of drug molecules on the protein structure in comparison to the native. Next, we analyzed the compactness of the native ACE2 and docked complexes by using the radius of gyration (Rg) calculations. The results showed that the Rg values of the native-ACE2 receptor and the complexes of anidulafungin, lopinavir, indinavir and MLN-4760 compounds remained highly stable with ranges of 2.78nm, 2.86nm, 2.82nm, 2.76nm and 2.77nm, respectively, throughout the MD simulation period (**Figure 3C** and **Table 2**). The low oscillations in Rg and SASA values portrayed high stability for the anidulafungin-ACE2 complex compared to other complexes and ACE2 alone. Interestingly, the Rg results also revealed that the ACE2-anidulafungin complex is most stable in all tested complexes. Comparative analysis of the Rg values shows the folding behaviour of ACE2 upon binding with anidulafungin which indicates high compactness between the complexes. We also performed a SASA analysis to better understand the solvent behaviour of native ACE2 and docked complexes. Here, we found an average value of native ACE2, anidulafungin, lopinavir, indinavir and MLN-4760 complexes 389.88nm², 392.60 nm², 391.05nm², 389.90nm² and 392.10nm², respectively (**Figure 3D** and **Table 2**). These results showed that the compound anidulafungin possessed more stable hydrophobic contacts than the other docked complexes, making most of the ACE2 receptor surface accessible to the solvent and other molecules.

Finally, the docked complexes were also subjected for the overall motion of all protein and drugs atoms by using **Free Energy Landscapes (FEL)** analysis. The conformational

stabilities of the native ACE2 and the docked complexes were examined by FEL analysis by using PC1 (Principal Components) and PC2 values. The values of FEL ranged from 0KJ/mol to 14KJ/mol, 12.9KJ/mol, 13KJ/mol, 12.9KJ/mol and 14.4KJ/mol for the native ACE2, anidulafungin, lopinavir, indinavir and MLN-4760 docked complexes, respectively (**Figure 4A-E**). This analysis indicated that the complexes were stable and persistent energy minima, suggesting the amino acids of the ACE2 binding pocket-forming interactions with drugs are vital for the stability and interaction. The global free energy minima results showed that the docked complexes revealed stabilizing effect leads to the observed folding behavior of ACE2 with anidulafungin. The analysis revealed that the anidulafungin (Figure 4B) is having less basins, compared to the native receptor with three basins (Figure 4A). Overall, the results for the anidulafungin complex revealed the presence of two basins in the conformational space, with distinct global free energy minima, which consequently leads to a more stable behavior of the protein.

3.3 Anidulafungin and lopinavir inhibits SARS-CoV-2 Spike-induced syncytia formation

The SARS-CoV-2 spike protein in the viral envelope is essential for virus entry into the target cells. The SARS-CoV-2 S protein induces cell-cell fusion and formation of syncytia when it is ectopically expressed on the membrane of host cells and binds ACE2 receptors of adjacent cells (Bussani et al., 2020; Xia et al., 2020; Braga et al., 2021; Buchrieser et al., 2021; Gutmann et al., 2021). Therefore, we explored whether S-induced syncytia formation would be impaired in the presence of the selected drugs anidulafungin, lopinavir, indinavir and MLN-4760, which shows high affinity towards the ACE2 receptor an *in-silico* analysis (**Figure 2 and Suppl. Figure 1**). First, we tested the effect of drugs in S-mediated syncytia formation in Vero cells, which our previous studies have shown to respond to S expression by fusion (Braga et al., 2021). After 6 hours of S-protein expression, cells were treated with indicated drugs at 10 μ M (Workflow shown in **Figure 5A**). Niclosamide (2.5 μ M) was used as a positive control because this drug is a potent inhibitor of S-mediated syncytia formation by acting on the cellular TMEM16F membrane protein (Braga et al., 2021). Interestingly, we observed that both anidulafungin and lopinavir treatment significantly reduced the S-mediated cell-cell fusion compared with DMSO treated control cells (**Figure 5 B and C**). As expected, niclosamide treatment significantly reduced syncytia formation (**Figure 5 B and C**). Both indinavir (Vacca et al., 1994; Condra et al., 1996) and MLN-4760 (Dales et al., 2002b; Joshi et al., 2016) were ineffective in blocking S-mediated cell fusion (**Figure 5 B and C**). None of the tested drug treatments interfered with ACE2 expression in the cells (**Suppl. Figure 2**). Additionally, we neither observed significant toxicity of the tested drugs (**Suppl. Figure 3**) nor any effect on S-transgene expression (**Suppl. Figure 4**). Together, these results are consistent with the conclusion that the observed effects of both anidulafungin and lopinavir are due to interference between ACE2-S interactions.

3.4 Anidulafungin and lopinavir inhibit SARS-CoV-2 Spike-viral particles entry

Entry of SARS-CoV-2 S-viral particles mimics the entry pathway of SARS-CoV-2 virions (Lu et al., 2020; Mykytyn et al., 2021). Therefore, we explored whether entry of pseudotyped lentiviral vectors expression S on their envelope would be impaired in the presence of the top selected drugs. For this purpose, HEK cells expressing the ACE2 receptor were treated with indicated drugs one hour before the addition of S-pseudotyped viral particles to the cells (Workflow shown in **Figure 6A**). Strikingly, we found that both anidulafungin and lopinavir treatment significantly impaired S-pseudo particles transduction (**Figure 6B and 6C**), while no significant effect was observed in the presence of indinavir and MLN-4760. In particular, anidulafungin, which showed the strongest affinity towards the ACE2 receptor in our in-

silico analysis and formed the most stable complex with ACE2 throughout the MD simulation period, was also the most effective in blocking S-mediated virion internalization. Collectively, these results indicate that anidulafungin impedes both S-mediated syncytia formation and S-viral particle entry into the target cells.

4 Discussion

In this work, we screened the FDA-approved antiviral dataset using the molecular docking approach and selected the best three compounds, namely anidulafungin, lopinavir and indinavir, which show strong binding affinity towards the ACE2 receptor.

Both lopinavir and indinavir are antiretroviral drugs that inhibit HIV-1 replication by targeting viral protease (Lv et al., 2015). Growing pieces of evidence suggest that lopinavir has an antiviral activity against SARS-CoV-2 (Choy et al., 2020). It has been proposed that it also inhibits the action of SARS-Cov-2 protease 3CLpro, hence disrupting the viral replication process (Anand et al., 2003; Zhang et al., 2020). However, coronavirus proteases, including 3CLpro, do not contain a C2-symmetric pocket, which is the target of HIV protease inhibitors (Li and De Clercq, 2020; Sheahan et al., 2020). Moreover, Darunavir, another HIV protease inhibitor, is ineffective against SARS-CoV-2 as revealed in a non-peer reviewed *in vitro* study (Johnson, 2020). Therefore, the reported anti-SARS-CoV-2 effects of lopinavir might be due to its affinity towards the ACE2 receptor, which leads to disruption of ACE2-Spike interaction; however, this requires further validation.

Anidulafungin is an anti-fungal lipo-peptide drug approved to treat invasive candidiasis, candidemia and esophageal candidiasis. It targets the critical enzyme 1,3- β -D-glucan synthase, essential for the fungal cell wall synthesis (Debono et al., 1995). In molecular dynamic simulations, all the three drug complexes with ACE2 were more stable than native-ACE2 and MLN-4670 inhibitors. Moreover, anidulafungin-ACE2 docked complex was most stable during MD analysis and exhibited an excellent binding affinity and energy of -14.42 kcal/mol and ΔG -162.28 kcal/mol, respectively. The MD simulation analysis also confirmed that the anidulafungin-ACE2 complex was stable, indicating that it can effectively block the ACE2 receptor sites by interacting with critical amino acid residues. Recently, an *in-silico* study also has shown that anidulafungin has an affinity towards ACE2 receptors (Ahsan and Sajib, 2021).

The SARS-CoV2 S protein plays a significant role in host cell viral attachment to receptor ACE2, and it also induces cell-cell fusion once expressed on the plasma membrane of ACE2-expressing cells. In our experiments, anidulafungin and lopinavir effectively blocked S-induced syncytia formation and S-pseudo particle entry into ACE2-expressing, target cells. Of interest, MLN-4760, an enzymatic inhibitor of ACE2 (Dales et al., 2002a), was ineffective in both blocking syncytia formation and S-pseudo particle entry. This indicates the relevance of ACE2 in S-mediated cell fusion and strengthens the conclusion that our top-performing drugs are effective by directly acting on this receptor.

In conclusion, our work discloses two drugs that appear to deserve further consideration as antiviral drugs for COVID-19 patients. However, further studies are required to fully understand their mechanism of action and potency against infectious SARS-CoV-2.

Statistical analysis

Mann-Whitney U significance test was used for the data analysis.

Conflict of Interest

None of the authors declare conflict of interests

Acknowledgements

MG acknowledges the British Heart Foundation (BHF) Programme Grant RG/19/11/34633. DG and SA acknowledge the Bioinformatics infrastructure grant to ICGEB by the Department of Biotechnology, Government of India (no. BT/PR40151/BTIS/137/5/2021). SA is a recipient of a Research Associate fellowship from the Indian Council of Medical Research (ICMR), India (2019–6039 File No. ISRM/11(83)/2019).

Figure legends

Figure 1. (A) Mechanism of action to prevent SARS-CoV-2 entry into the target host cell. SARS-CoV-2 enters human cells after the interaction of the Spike protein with the ACE2 receptor. Blocking ACE2-Spike interactions by targeting ACE2 receptors with antiviral compounds is an important approach for developing novel therapeutics against SARS-CoV2. (B) Schematic overview of searching novel inhibitors at the proposed study.

Figure 2. Docked all the 450 compounds with ACE2 receptor (A). The binding interaction H-bonds (green) the amino acid residues of ACE2 and Anidulafungin at the binding site (B). The 2D plot of the ACE2-anidulafungin binding pose (C).

Figure 3. The elucidation MD simulation of native ACE2 and ACE2-docked complexes, (A) Representation C-alpha conformation of RMSD, (B) Comparative RMS fluctuation plot of native ACE2 and ACE2-docked complexes (C) Rg analysis of native ACE2 and ACE2-docked complexes (D) SASA plot of native ACE2 and ACE2-docked complexes.

Figure 4. Free energy landscape analysis of (A) native ACE2 and complexes with Anidulafungin (B), Lopinavir (C), Indinavir (D) and MLN-4760 (E) compounds.

Figure 5. Anidulafungin and Lopinavir impaired the Spike-mediated syncytia formation. A) Schematic representation of the SARS-Cov2 Spike-mediated cell-cell fusion assay. B) Vero cells were treated with either DMSO or top 3 selected drugs after 8 hrs of Spike expressing plasmid transfection. After 20 hr, cells were immunostained with anti-Spike (green) and nuclei (blue). C) Quantifications. Data (mean±SD; n=6, Mann-Whitney U test) are plotted as the percentage of fused cells (syncytia) normalized on the total number of cells.

Figure 6. Anidulafungin impaired the Spike-pseudo particle internalisation

A) Schematic representation of the SARS-Cov2 Spike pseudo particle sentry assay. B, C) HEK293/ACE2 cells were pre-treated with indicated drugs 1-2 hrs before adding the Spike pseudo-particles carrying GFP as a reporter. After 36 hr, cells were immunostained with anti-GFP (green) and nuclei (blue). Representative images are in panel B (Spike pseudoparticles), and quantifications in panel C (Spike pseudoparticles Data (mean±SD; n=6, Mann-Whitney U test). Data are plotted as the percentage of GFP+ cells normalized on the total number of cells.

Table 1: Physical & Chemical Properties of selected four compounds, molecular docking based virtual screening H-bonds and Hydrophobic residues.

Table 2: The average values of RMSD, RMSF, Rg and SASA of the native ACE2 and complex containing the compounds Anidulafungin, Lopinavir, Indinavir and MLN-4760.

Suppl. Figure legends

Suppl. Figure 1. Interactions of docked complexes of ACE2 receptor. The binding interaction H-bonds (green) the amino acid residues of ACE2 and lopinavir at the binding site (A), Indinavir(B) and MLN-4670(C). The 2D plot of the docked ACE2-compounds binding pose, lopinavir (D), Indinavir (E) and MLN-4670(F).

Suppl. Figure 2. Indicated drugs toxicity.

Vero cells were treated with different concentration of the indicated drugs(10 μ M-1.25 μ M). After 24hr, cells were washed with PBS and fixed and stained to count the total number of cells. The graph shows the quantifications of total cells in the presence of drugs (data mean \pm SD; n=2)

Suppl. Figure 3. Indicated drugs did not alter the expression of transgene GFP.

A) Schematic representation of the drugs and their effects on GFP transgene expression assay. B-C). Vero cells were transfected with GFP expressing plasmid. After 6hr, cells were treated with indicated drugs (Lopinavir, Anidulafungin, Indinavir and ACE2-inhibitor) at 10 μ M and after 20hrs were immunoassayed with anti-GFP (green) and nuclei (blue). Representative images are in panel B, and quantifications in panel C (% of GFP+ cells, data (mean \pm SD; n=2). Data are plotted as the total cells and percentage of GFP+ cells normalized on the total number of cells.

Suppl. Figure 4. ACE2 expression in the presence of tested drugs.

Expression levels of ACE2 in the presence of tested drugs (Lopinavir, Anidulafungin, Indinavir and ACE2-inhibitor). Vero cells were treated with different drugs at 10 μ M. After 24 hr, cells were collected and used for proteomic analysis. Levels of ACE2 and beta-actin were assessed by immunoblotting with anti-ACE2, anti-beta-actin antibodies, respectively.

Supplementary Table: All the drugs along physicochemical properties and docking scores obtained from Flare software.

References:

- Abraham M J, Murtola T, Schulz R, Páll S R, Smith J C, Hess B, Lindahl E (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX*, 1: 19-25
- Ahamad S, Hema K, Gupta D (2021a). Structural stability predictions and molecular dynamics simulations of RBD and HR1 mutations associated with SARS-CoV-2 spike glycoprotein. *Journal of Biomolecular Structure and Dynamics*: 1-13
- Ahamad S, Kanipakam H, Birla S, Ali M S, Gupta D (2021b). Screening Malaria-box compounds to identify potential inhibitors against SARS-CoV-2 Mpro, using molecular docking and dynamics simulation studies. *European journal of pharmacology*, 890: 173664
- Ahmad I, Pawara R, Surana S, Patel H (2021). The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19. *Topics in Current Chemistry*, 379(6): 1-49
- Ahsan T, Sajib A A (2021). Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor. *Biochem Biophys Rep*, 26: 100982
- Anand K, Ziebuhr J, Wadhwani P, Mesters J R, Hilgenfeld R (2003). Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science*, 300(5626): 1763-1767
- Beigel J H, Tomashek K M, Dodd L E (2020). Remdesivir for the Treatment of Covid-19- "Final Report" *N Engl J Med.*, 383(19): 1813-1836
- Braga L, Ali H, Secco I, Chiavacci E, Neves G, Goldhill D, Penn R, Jimenez-Guardeno J M, Ortega-Prieto A M, Bussani R (2021). Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia. *nature*, 594(7861): 88-93
- Buchrieser J, Dufloo J, Hubert M, Monel B, Planas D, Rajah M M, Planchais C, Porrot F, Guivel-Benhassine F, Van Der Werf S (2021). Syncytia formation by SARS-CoV-2-infected cells. *The EMBO journal*, 39(23): e106267
- Bussani R, Schneider E, Zentilin L, Collesi C, Ali H, Braga L, Volpe M C, Colliva A, Zanconati F, Berlot G, Silvestri F, Zacchigna S, Giacca M (2020). Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology. *EBioMedicine*, 61: 103104
- Cantuti-Castelvetri L, Ojha R, Pedro L D, Djannatian M, Franz J, Kuivanen S, Van Der Meer F, Kallio K, Kaya T, Anastasina M, Smura T, Levanov L, Szirovicza L, Tobi A, Kallio-Kokko H, Osterlund P, Joensuu M, Meunier F A, Butcher S J, Winkler M S, Mollenhauer B, Helenius A, Gokce O, Teesalu T, Hepojoki J, Vapalahti O, Stadelmann C, Balistreri G, Simons M (2020). Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science*, 370(6518): 856-860
- Carlos A J, Ha D P, Yeh D-W, Van Krieken R, Tseng C-C, Zhang P, Gill P, Machida K, Lee A S (2021). The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection. *Journal of Biological Chemistry*, 296
- Chen C Z, Shinn P, Itkin Z, Eastman R T, Bostwick R, Rasmussen L, Huang R, Shen M, Hu X, Wilson K M (2021). Drug repurposing screen for compounds inhibiting the cytopathic effect of SARS-CoV-2. *Frontiers in Pharmacology*: 2005
- Choy K T, Wong A Y, Kaewpreedee P, Sia S F, Chen D, Hui K P Y, Chu D K W, Chan M C W, Cheung P P, Huang X, Peiris M, Yen H L (2020). Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Res*, 178: 104786
- Condra J H, Holder D J, Schleif W A, Blahy O M, Danovich R M, Gabryelski L J, Graham D J, Laird D, Quintero J C, Rhodes A, Robbins H L, Roth E, Shivaprakash M, Yang T, Chodakewitz J A, Deutsch P J, Leavitt R Y, Massari F E, Mellors J W, Squires K E, Steigbigel R T, Teppler H, Emini E A (1996). Genetic correlates of in vivo viral resistance to

indinavir, a human immunodeficiency virus type 1 protease inhibitor. *J Virol*, 70(12): 8270-8276

Dales N A, Gould A E, Brown J A, Calderwood E F, Guan B, Minor C A, Gavin J M, Hales P, Kaushik V K, Stewart M (2002a). Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. *Journal of the American Chemical Society*, 124(40): 11852-11853

Dales N A, Gould A E, Brown J A, Calderwood E F, Guan B, Minor C A, Gavin J M, Hales P, Kaushik V K, Stewart M, Tummino P J, Vickers C S, Ocain T D, Patane M A (2002b). Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. *J Am Chem Soc*, 124(40): 11852-11853

Debono M, Turner W W, Lagrandeur L, Burkhardt F J, Nissen J S, Nichols K K, Rodriguez M J, Zweifel M J, Zeckner D J, Gordee R S, Et Al. (1995). Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. *J Med Chem*, 38(17): 3271-3281

Dittmar M, Lee J S, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz F L, Morrissey E E, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz D C, Cherry S (2021). Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. *Cell Rep*, 35(1): 108959

Elfiky A A, Ibrahim I M (2022). Host-cell recognition through Cs-GRP78 is enhanced in the new Omicron variant of SARS-CoV-2, in silico structural point of view. *Journal of Infection*, 10:32

Ellinger B, Bojkova D, Zaliani A, Cinatl J, Claussen C, Westhaus S, Keminer O, Reinshagen J, Kuzikov M, Wolf M, Geisslinger G, Gribbon P, Ciesek S (2021). A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. *Sci Data*, 8(1): 70

Ghahremanpour M M, Tirado-Rives J, Deshmukh M, Ippolito J A, Zhang C-H, Cabeza De Vaca I, Liosi M-E, Anderson K S, Jorgensen W L (2020). Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. *ACS medicinal chemistry letters*, 11(12): 2526-2533

Ginex T, Garaigorta U, Ramirez D, Castro V, Nozal V, Maestro I, Garcia-Carceles J, Campillo N E, Martinez A, Gastaminza P, Gil C (2021). Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. *Pharmaceuticals (Basel)*, 14(4): 332

Goodsell D S, Zardecki C, Di Costanzo L, Duarte J M, Hudson B P, Persikova I, Segura J, Shao C, Voigt M, Westbrook J D, Young J Y, Burley S K (2020). RCSB Protein Data Bank: Enabling biomedical research and drug discovery. *Protein Sci*, 29(1): 52-65

Gutmann C, Takov K, Burnap S A, Singh B, Ali H, Theofilatos K, Reed E, Hasman M, Nabeebaccus A, Fish M, Mcphail M J, O'gallagher K, Schmidt L E, Cassel C, Rienks M, Yin X, Auzinger G, Napoli S, Mujib S F, Trovato F, Sanderson B, Merrick B, Niazi U, Saqi M, Dimitrakopoulou K, Fernandez-Leiro R, Braun S, Kronstein-Wiedemann R, Doores K J, Edgeworth J D, Shah A M, Bornstein S R, Tonn T, Hayday A C, Giacca M, Shankar-Hari M, Mayr M (2021). SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. *Nat Commun*, 12(1): 3406

Han Y, Duan X, Yang L, Nilsson-Payant B E, Wang P, Duan F, Tang X, Yaron T M, Zhang T, Uhl S (2021). Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. *nature*, 589(7841): 270-275

Heiser K, Mclean P F, Davis C T, Fogelson B, Gordon H B, Jacobson P, Hurst B, Miller B, Alfa R W, Earnshaw B A (2020). Identification of potential treatments for COVID-19

through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2. *BioRxiv*,

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens T S, Herrler G, Wu N-H, Nitsche A (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *cell*, 181(2): 271-280. e278

Ibrahim I M, Abdelmalek D H, Elshahat M E, Elfiky A A (2020). COVID-19 spike-host cell receptor GRP78 binding site prediction. *Journal of Infection*, 80(5): 554-562

Jeon S, Ko M, Lee J, Choi I, Byun S Y, Park S, Shum D, Kim S (2020). Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. *Antimicrob Agents Chemother*, 64(7): e00819-00820

Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C (2020). Structure of M pro from SARS-CoV-2 and discovery of its inhibitors. *nature*, 582(7811): 289-293

Johnson B A, Xie X, Kalveram B, Lokugamage K G, Muruato A, Zou J, Zhang X, Juelich T, Smith J K, Zhang L (2020). Furin cleavage site is key to SARS-CoV-2 pathogenesis. *BioRxiv*,

Johnson J (2020). Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2. www.jnj.com: Janssen

Joshi S, Balasubramanian N, Vasam G, Jarajapu Y P (2016). Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. *Eur J Pharmacol*, 774: 25-33

Ku K B, Shin H J, Kim H S, Kim B T, Kim S J, Kim C (2020). Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2. *J Microbiol Biotechnol*, 30(12): 1843-1853

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *nature*, 581(7807): 215-220

Lee J, Cheng X, Swails J M, Yeom M S, Eastman P K, Lemkul J A, Wei S, Buckner J, Jeong J C, Qi Y (2016). CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. *Journal of chemical theory and computation*, 12(1): 405-413

Li G, De Clercq E (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). *Nat Rev Drug Discov*, 19(3): 149-150

Liu Z, Vanblargan L A, Bloyet L-M, Rothlauf P W, Chen R E, Stumpf S, Zhao H, Errico J M, Theel E S, Liebeskind M J (2021). Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell host & microbe*, 29(3): 477-488. e474

Lu M, Uchil P D, Li W, Zheng D, Terry D S, Gorman J, Shi W, Zhang B, Zhou T, Ding S (2020). Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles. *Cell host & microbe*, 28(6): 880-891. e888

Lv Z, Chu Y, Wang Y (2015). HIV protease inhibitors: a review of molecular selectivity and toxicity. *HIV AIDS (Auckl)*, 7: 95-104

Magro P, Zanella I, Pescarolo M, Castelli F, Quiros-Roldan E (2021). Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment. *Biomed J*, 44(1): 43-53

Marovich M, Mascola J R, Cohen M S (2020). Monoclonal antibodies for prevention and treatment of COVID-19. *Jama*, 324(2): 131-132

Mirabelli C, Wotring J W, Zhang C J, Mccarty S M, Fursmidt R, Pretto C D, Qiao Y, Zhang Y, Frum T, Kadambi N S (2021). Morphological cell profiling of SARS-CoV-2 infection

identifies drug repurposing candidates for COVID-19. *Proceedings of the National Academy of Sciences*, 118(36)

Mykytyn A Z, Breugem T I, Riesebosch S, Schipper D, Van Den Doel P B, Rottier R J, Lamers M M, Haagmans B L (2021). SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. *Elife*, 10: e64508

Nguyenla X, Wehri E, Van Dis E, Biering S, Yamashiro L H, Stroumza J, Dugast-Darzacq C, Graham T, Stanley S, Schaletzky J (2020). Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. *BioRxiv*,

Otto S P, Day T, Arino J, Colijn C, Dushoff J, Li M, Mechai S, Van Domselaar G, Wu J, Earn D J D, Ogden N H (2021). The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. *Curr Biol*, 31(14): R918-R929

Peacock T P, Goldhill D H, Zhou J, Baillon L, Frise R, Swann O C, Kugathasan R, Penn R, Brown J C, Sanchez-David R Y (2021). The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. *Nature Microbiology*: 1-11

Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, Buchrieser J, Rajah M M, Bishop E, Albert M, Donati F, Prot M, Behillil S, Enouf V, Maquart M, Smati-Lafarge M, Varon E, Schortgen F, Yahyaoui L, Gonzalez M, De Seze J, Pere H, Veyer D, Seve A, Simon-Lorriere E, Fafi-Kremer S, Stefic K, Mouquet H, Hocqueloux L, Van Der Werf S, Prazuck T, Schwartz O (2021). Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *Nat Med*, 27(5): 917-924

Pouwels K B, Pritchard E, Matthews P C, Stoesser N, Eyre D W, Vihta K D, House T, Hay J, Bell J I, Newton J N, Farrar J, Crook D, Cook D, Rourke E, Studley R, Peto T E A, Diamond I, Walker A S (2021). Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. *Nat Med*, 27(12): 2127-2135

Price D J, Brooks C L, 3rd (2004). A modified TIP3P water potential for simulation with Ewald summation. *J Chem Phys*, 121(20): 10096-10103

Rees-Spear C, Muir L, Griffith S A, Heaney J, Aldon Y, Snitselaar J L, Thomas P, Graham C, Seow J, Lee N, Rosa A, Roustan C, Houlihan C F, Sanders R W, Gupta R K, Cherepanov P, Stauss H J, Nastouli E, Investigators S, Doores K J, Van Gils M J, McCoy L E (2021). The effect of spike mutations on SARS-CoV-2 neutralization. *Cell Rep*, 34(12): 108890

Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus P D, Teriete P, Hull M V (2020). Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. *nature*, 586(7827): 113-119

Sanders D W, Jumper C C, Ackerman P J, Bracha D, Donlic A, Kim H, Kenney D, Castello-Serrano I, Suzuki S, Tamura T, Tavares A H, Saeed M, Holehouse A S, Ploss A, Levental I, Douam F, Padera R F, Levy B D, Brangwynne C P (2021). SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. *Elife*, 10: e65962

Sanderson K (2021). COVID vaccines protect against Delta, but their effectiveness wanes. *nature*,

Schuttelkopf A W, Van Aalten D M (2004). PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. *Acta Crystallogr D Biol Crystallogr*, 60(Pt 8): 1355-1363

Sheahan T P, Sims A C, Leist S R, Schafer A, Won J, Brown A J, Montgomery S A, Hogg A, Babusis D, Clarke M O, Spahn J E, Bauer L, Sellers S, Porter D, Feng J Y, Cihlar T, Jordan R, Denison M R, Baric R S (2020). Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun*, 11(1): 222

Singh J, Pandit P, McArthur A G, Banerjee A, Mossman K (2021). Evolutionary trajectory of SARS-CoV-2 and emerging variants. *Virol J*, 18(1): 166

Starr T N, Greaney A J, Addetia A, Hannon W W, Choudhary M C, Dingens A S, Li J Z, Bloom J D (2021). Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. *Science*, 371(6531): 850-854

Sterne J A, Murthy S, Diaz J V, Slutsky A S, Villar J, Angus D C, Annane D, Azevedo L C P, Berwanger O, Cavalcanti A B (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *Jama*, 324(13): 1330-1341

Taylor P C, Adams A C, Hufford M M, De La Torre I, Winthrop K, Gottlieb R L (2021). Neutralizing monoclonal antibodies for treatment of COVID-19. *Nature Reviews Immunology*: 1-12

Touret F, Gilles M, Barral K, Nougairede A, Van Helden J, Decroly E, De Lamballerie X, Coutard B (2020). In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. *Sci Rep*, 10(1): 13093

Vacca J P, Dorsey B D, Schleif W A, Levin R B, Mcdaniel S L, Darke P L, Zugay J, Quintero J C, Blahy O M, Roth E, Et Al. (1994). L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. *Proc Natl Acad Sci U S A*, 91(9): 4096-4100

Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark A E, Berendsen H J (2005). GROMACS: fast, flexible, and free. *Journal of computational chemistry*, 26(16): 1701-1718

Wang H, Nakamura H, Fukuda I (2016). A critical appraisal of the zero-multipole method: Structural, thermodynamic, dielectric, and dynamical properties of a water system. *J Chem Phys*, 144(11): 114503

Wang L, Wu Y, Yao S, Ge H, Zhu Y, Chen K, Chen W-Z, Zhang Y, Zhu W, Wang H-Y (2021). Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. *Acta Pharmacologica Sinica*: 1-9

Weisblum Y, Schmidt F, Zhang F, Dasilva J, Poston D, Lorenzi J C C, Muecksch F, Rutkowska M, Hoffmann H-H, Michailidis E (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife*, 9: e61312

Weston S, Coleman C M, Haupt R, Logue J, Matthews K, Li Y, Reyes H M, Weiss S R, Frieman M B (2020). Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. *J Virol*, 94(21): e01218-01220

Who (2022). WHO Coronavirus (COVID-19) Dashboard With Vaccination Data: World Health Organization

Wrapp D, Wang N, Corbett K S, Goldsmith J A, Hsieh C-L, Abiona O, Graham B S, McLellan J S (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*, 367(6483): 1260-1263

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S (2020). Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. *Cell research*, 30(4): 343-355

Xiu S, Dick A, Ju H, Mirzaie S, Abdi F, Cocklin S, Zhan P, Liu X (2020). Inhibitors of SARS-CoV-2 entry: current and future opportunities. *Journal of medicinal chemistry*, 63(21): 12256-12274

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020). Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science*, 367(6485): 1444-1448

Yuan S, Chan J F W, Chik K K H, Chan C C Y, Tsang J O L, Liang R, Cao J, Tang K, Chen L-L, Wen K (2020). Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. *Pharmacological research*, 159: 104960

Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R (2020). Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors. *Science*, 368(6489): 409-412

Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, Yang D, Zhang G, Li H, Chen F, Xu Y, Chen M, Gao Z, Yang J, Dong J, Liu B, Zhang X, Wang W, He K, Jin Q, Li M, Wang J (2020). Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. *Cell Host Microbe*, 27(6): 883-890 e882

Zhu N, Wang W, Liu Z, Liang C, Wang W, Ye F, Huang B, Zhao L, Wang H, Zhou W, Deng Y, Mao L, Su C, Qiang G, Jiang T, Zhao J, Wu G, Song J, Tan W (2020). Morphogenesis and cytopathic effect of SARS-CoV-2 infection in human airway epithelial cells. *Nat Commun*, 11(1): 3910

Table 1. The shortlisted compounds physicochemical properties of Anidulafungin, Lopinavir, Indinavir and MLN-4760.

| Compounds | Anidulafungin | lopinavir | Indinavir | MLN-4670 |
|--|---|--|--|---|
| MW | 1140.3 | 628.8 | 613.8 | 428.3 |
| Atoms | 82 | 46 | 45 | 28 |
| SlogP | 2.1 | 4.7 | 3.6 | 3.4 |
| TPSA | 377.4 | 120 | 118 | 104.4 |
| RB | 38 | 16 | 14 | 12 |
| dG | -12.96 | -8.77 | -8.93 | -11.11 |
| LF VSscore | -14.24 | -11.05 | -10.56 | -11.46 |
| LF RankScore | -14.42 | -12.97 | -12.94 | -9.78 |
| H-bounds | Arg518 and Thr371 | Glu398 | Gly395 and Glu402 | Glu402 |
| Residues forming hydrophobic interactions | Asp206, Arg273, Phe274, Thr276, Asp367, Leu370, Thr371, His345, Pro346, His374, Glu375, Asn394, Gly395, Ala396, Asn397, Glu398, Gly399, His401, Glu402, Gly405, Glu406, Ile407, Ser409, Leu410, Lys441, Gln442, Thr445, Ile446, Gln522, Arg514, Tyr515, Lys562 and Zn | Phe40, Asp206, Tyr207, Arg273, His345, Pro346, Thr347, Ala348, Trp349, Asp350, Leu351, His374, Glu375, His378, Ile379, Tyr381, Asp382, Tyr385, Arg393, Asn394, Gly395, Ala396, Asn397, Glu398, Gly399, Phe400, His401, Glu402, Ala403, Ile513, Arg514, Tyr515, Tyr516, Thr517, Arg518, Thr519, Tyr521, Lys562 and Zn | Phe40, Asp206, His345, Pro346, Thr347, Ala348, Trp349, Asp350, Leu351, Gly352, Phe356, His374, Glu375, His378, Tyr381, Asp382, Tyr385, Phe390, Arg393, Asn394, Ala396, Asn397, Glu398, Gly399, Phe400, His401, Ala403, Arg514, Tyr515, Thr517, Arg518, Thr519 and Zn | Arg273, His345, Pro346, Thr347, Ala348, Met360, Asp367, Asp368, Thr371, His374, Glu375, His378, Asn397, Glu398, Gly399, Phe400, His401, Ala403, Gly405, Glu406, His505, Arg514, Tyr515, Tyr516, Arg518 and Zn |
| MMGBSA (ΔG) | -162.28 | -67.19 | -92.1 | -73.53 |

Table 2. The average values of RMSD, Rg and SASA of the native ACE2 and complex containing compounds Anidulafungin, Lopinavir, Indinavir and MLN-4760.

| <i>Complexes</i> | <i>Average RMSD (nm)</i> | <i>Average RMSF (nm)</i> | <i>Average SASA (nm²)</i> | <i>Average Rg (nm)</i> |
|---------------------------|--------------------------|--------------------------|--------------------------------------|------------------------|
| <i>Native-ACE2</i> | <i>0.44</i> | <i>0.18</i> | <i>389.88</i> | <i>2.78</i> |
| <i>ACE2-anidulafungin</i> | <i>0.39</i> | <i>0.14</i> | <i>392.60</i> | <i>2.86</i> |
| <i>ACE2-lopinavir</i> | <i>0.41</i> | <i>0.18</i> | <i>391.05</i> | <i>2.82</i> |
| <i>ACE2-Indinavir</i> | <i>0.45</i> | <i>0.15</i> | <i>389.90</i> | <i>2.76</i> |
| <i>ACE2-MLN-4760</i> | <i>0.41</i> | <i>0.18</i> | <i>392.10</i> | <i>2.77</i> |